Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment
核心洞察
DelveInsight's latest pipeline report identifies over 20 pharmaceutical companies actively developing treatments for c-MET-positive Non-Small Cell Lung Cancer, with multiple promising candidates in various clinical stages.
AbbVie (搜索)'s telisotuzumab vedotin enters Phase 3 trials in January 2025, comparing its efficacy against docetaxel in previously treated c-Met overexpressing NSCLC patients.
Key players including AbbVie (搜索), Janssen, and Beijing Pearl Biotechnology (搜索) are advancing novel therapeutic approaches, from bispecific antibodies to targeted small molecules for c-MET NSCLC treatment.
A comprehensive pipeline analysis has revealed a robust development landscape for c-MET-positive Non-Small Cell Lung Cancer (NSCLC) treatments, with more than 20 pharmaceutical companies actively advancing therapeutic candidates through various stages of development.
AbbVie (搜索) is leading a significant Phase 3 clinical trial starting January 2025, evaluating telisotuzumab vedotin (ABBV-399) against docetaxel in previously treated patients. This open-label, randomized, controlled global study specifically targets individuals with c-Met overexpressing, EGFR wildtype, locally advanced or metastatic non-squamous NSCLC.
Novel Therapeutic Approaches
Among the promising candidates, Janssen Research & Development (搜索)'s JNJ-61186372 stands out as an innovative EGFR-MET bispecific antibody. Developed using Genmab's DuoBody technology platform, this antibody targets both activating and resistant EGFR and MET mutations and amplifications. The drug shows particular promise for patients with Exon 20 mutation insertions, who typically show limited response to existing EGFR-targeted therapies and immune checkpoint inhibitors.
Beijing Pearl Biotechnology (搜索) is advancing PLB1001, an oral c-Met inhibitor designed to disrupt cancer cell survival pathways. The drug works by selectively binding to c-Met, inhibiting phosphorylation and signal transduction pathways in tumor cells that overexpress the c-Met protein.
Diverse Treatment Modalities
The pipeline encompasses various therapeutic approaches, including:
- Small molecules
- Bispecific antibodies
- Immunotherapies
- Monoclonal antibodies
- Gene therapies
These treatments are being developed for different routes of administration, ranging from oral and intramuscular to intravenous and intratumoral delivery methods.
Key Pipeline Candidates
Several other promising therapies are in development, including:
- Glumetinib
- Tepotinib
- INC280 (Novartis)
- APL-101 Oral Capsules
- MCLA-129
- Osimertinib
Development Landscape
The current pipeline features drugs across multiple development stages, from discovery and preclinical to Phase III trials. This diverse development landscape suggests a strong potential for new treatment options for c-MET+ NSCLC (搜索) patients in the coming years.
Industry leaders including AbbVie (搜索), Janssen Research & Development (搜索), Beijing Pearl Biotechnology (搜索), and Novartis are investing significant resources in developing these targeted therapies, reflecting the growing importance of precision medicine in oncology treatment strategies.